Cargando…
Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors
BACKGROUND: Pucotenlimab is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb) with a S228P hinge mutation and an engineered Fc domain. Preclinical data suggests that pucotenlimab exerts antitumor effects. In this phase I study, which was...
Autores principales: | Liu, Rujiao, Li, Wenhua, Meng, Yanchun, Gao, Shuiping, Zhang, Jian, Hu, Xichun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182631/ https://www.ncbi.nlm.nih.gov/pubmed/34158838 http://dx.doi.org/10.1177/17588359211020528 |
Ejemplares similares
-
Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer
por: Cao, Jun, et al.
Publicado: (2022) -
Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study
por: Cui, Chuanliang, et al.
Publicado: (2023) -
Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours
por: Zhang, Jian, et al.
Publicado: (2023) -
HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties
por: Zhang, Jibin, et al.
Publicado: (2020) -
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
por: Song, Yan, et al.
Publicado: (2020)